Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Finally, colonic IL-8+ T cells co-expressed GM-CSF, TNF- and IL-6 were detected ex vivo and, promoted by IL-12 in the mucosa and mLNs in UC only.
|
31206576 |
2020 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Oscillibacter abundance was significantly positively correlated with IL-6 and IL-1β levels and pathological score, and Oscillibacter was increased in UC mice.
|
31689519 |
2019 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
S. boulardii treatment reduced AOM/DSS-induced UC carcinogenesis in mice, as indicated by the reduced tumor load and reduced TNF-α and IL-6 levels in vivo, as well its effects on TNF-α and IL-6 activities in vitro.
|
31694526 |
2019 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Expression levels of IgA and sIgA decreased, while IL-6, IL-8 and TNF-α further increased in the stress-treated UC mice (P<0.05).
|
30783488 |
2019 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
It is found that the anti-UC activities are mainly focused on targeting inflammation or oxidative stress, which is associated with increasing the levels of anti-inflammatory cytokine (IL-4, IL-10, SOD), suppressing the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-23, NF-κB, NO), reducing the activity of MPO, MDA, IFN-γ, and iNOS.
|
30797423 |
2019 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The levels of IL-6 and TNF-α in peripheral blood in the UC patient group were significantly increased compared with those in the healthy adult group (P<0.01), while the levels of IL-10 and IL-4 in peripheral blood were significantly decreased compared with those in the healthy adult group (P<0.01).
|
30906432 |
2019 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Circulating monocytes from active ulcerative colitis (UC) patients produced high levels of tumor necrosis factor-alpha(TNFα) and interleukin(IL)-6 after Toll-like receptors (TLR) stimulation.
|
29529212 |
2018 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CX-10 treatment attenuated DSS-induced UC in mice through inhibiting the activation of NF-κB and MAPK pathways and reducing TNF-α and IL-6 levels, suggesting that CX-10 is a potential therapeutic drug for UC.
|
29475099 |
2018 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Therefore, suppression of IL‑6/STAT3 signaling provides a promising therapeutic strategy in UC.
|
29845215 |
2018 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to evaluate the serum and stool IL-1β, IL-1ra and IL-6 concentrations as potential prognostic factors in children with UC.
|
29379540 |
2018 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.
|
29171305 |
2018 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Also HASG was found to reduce the levels of TNF-α and IL-6, thereby suppressing their inflammatory response in UC.
|
29530609 |
2018 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
IL-6 serum levels were significantly elevated in active versus inactive CD and UC, also compared with healthy controls.
|
29748708 |
2018 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
During CMV lytic infection, pro-inflammatory cytokines IL-6 and TNF-α increased remarkably and anti-inflammatory cytokine IL-5 decreased, which may exacerbate UC.
|
29226079 |
2017 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Both children and adults had decreased multidrug resistance protein 1 expression in colon, which inversely correlated with disease score, IL-6 and interferon-γ levels in UC-New children.
|
27622899 |
2017 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
MSE decreased colonic secretions of pro-inflammatory keratinocyte-derived cytokine (KC), tumor necrosis factor (TNF)-α, nitric oxide (NO), and myeloperoxidase (MPO) in acute and chronic UC; reduced fecal lipocalin-2 in acute UC; downregulated gene expression of pro-inflammatory interleukin (IL)-1, IL-6, TNF-α, and inducible nitric oxide synthase (iNOS) in acute UC; upregulated expression of claudin-1 and ZO-1 in acute and chronic UC; and upregulated GSTP1, an Nrf2-mediated phase II detoxifying enzyme, in chronic UC.
|
28922365 |
2017 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In addition, TL exerted therapeutic effects in UC through inhibition of IL-6 expression.
|
28962154 |
2017 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Multiple regression showed IL1β and IL13 to be the independent predictors of circulating IL9 in healthy individuals, IFNγ or IL6 in active and inactive UC, respectively, and IL13 and VEGF-A in both active and inactive CD.
|
28652656 |
2017 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Differences between higher mRNA expression of FoxP3 and IL-6 in inflamed tissue were considered significant in patients with ulcerative colitis (UC) (p=0.011, p=0.000 respectively) and with Crohn's disease (CD) (p=0.008, p=0.000 respectively) in comparison to the normal mucosa of non-IBD persons and we found increased TGFβ1 in CD patients alone (p=0.041).
|
28088612 |
2017 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Inhibition of IL-6 by tocilizumab had no clinical benefit in this patient with intractable ulcerative colitis and even led to exacerbation of mucosal inflammation.
|
26668517 |
2015 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The results of this study indicate that both chronic HIV infection and UC are associated with similar patterns of IL-6, IL- 8, and HD5 expression in colorectal biopsy tissue.
|
25768924 |
2015 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Comparison to established steroid sensitivity marker IL-6 confirmed that clinical responders are steroid refractory UC patients.
|
24758565 |
2014 |
Ulcerative Colitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Relatively low IL-10 in patients with severe UC is insufficient to compensate IL-6 secretion and subsequently enhanced type 1/17 immune response.
|
25076849 |
2014 |
Ulcerative Colitis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Nineteen functional polymorphisms that alter the NFκB-mediated inflammatory response (TLR2 (rs3804099, rs11938228, rs1816702, rs4696480), TLR4 (rs5030728, rs1554973), TLR9 (rs187084, rs352139), LY96 (MD-2) (rs11465996), CD14 (rs2569190), MAP3K14 (NIK) (rs7222094)), TNF-α signaling (TNFA (TNF-α) (rs361525), TNFRSF1A (TNFR1) (rs4149570), TNFAIP3(A20) (rs6927172)) and other cytokines regulated by NFκB (IL1B (rs4848306), IL1RN (rs4251961), IL6 (rs10499563), IL17A (rs2275913), IFNG (rs2430561)) were associated with response to anti-TNF therapy among patients with CD, UC or both CD and UC (P ⩽ 0.05).
|
24776844 |
2014 |
Ulcerative Colitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Colonic interleukin (IL)-17+, IL-22, and IL-6 mRNA upregulation and increase in the number of colonic IL-17 cells were demonstrated in both Crohn disease (CD) and ulcerative colitis (UC).
|
23974060 |
2013 |